Key Drivers
- Liquidity strength
- Operating losses
- Negative cash flow
AIAI Summary
CYRX has crossed into an early EBITDA inflection with healthy growth in higher-value services and a solid balance sheet, but until GAAP profitability and free cash flow turn positive, it remains a fragile turnaround that needs a sustained move back above $15.7–$16 to confirm the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity strength
- •Operating losses
- •Negative cash flow
CryoPort shows solid liquidity and stable gross margins, but weak operating performance, negative free cash flow, and rising valuation multiples point to a cautious outlook.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Lower highs
- •Near-term rebound
CYRX remains in a short-term downtrend over the last month, but its rebound above $15.00 from support near $14.71–$14.80 suggests near-term selling pressure may be easing unless $14.70 breaks.
Rebounded above $15.00 after holding support near $14.71-$14.80
Sentiment & News
Key News Insights:
- •Revenue Beat
- •EBITDA Turnaround
- •Buy Upgrade
CryoPort topped Q2 expectations with $49 million in revenue, achieved positive adjusted EBITDA, and reaffirmed full-year guidance, signaling improving momentum for CYRX.
The results and upbeat follow-up should support CYRX sentiment by highlighting improving profitability and durable growth in cell and gene therapy logistics
Similar Companies in Industrials
Other companies in the same sector with AI ratings